SCHEMBL2859433

SCHEMBL2859433

COc1cccc(CN(C(Cc2ccccc2)C(=O)NO)S(=O)(=O)c2ccc(OCCCCl)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.53
MMP9 P14780 4/20 0.53
MMP8 P22894 2/20 0.53
MMP13 P45452 2/20 0.53
BMP1 P13497 15/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859432 1.00 MMP2 (0.53) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2868139 0.92 MMP2 (0.59) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2868142 0.92 MMP2 (0.59) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2858314 0.92 BMP1 (0.58) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2858317 0.92 BMP1 (0.58) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2860031 0.92 MMP2 (0.58) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2860026 0.92 MMP2 (0.58) MMP2MMP9MMP8MMP13BMP1
SCHEMBL4082323 0.90 MMP2 (0.51) MMP2MMP9MMP8MMP13BMP1
SCHEMBL4082328 0.90 MMP2 (0.51) MMP2MMP9MMP8MMP13BMP1
SCHEMBL2856295 0.89 BMP1 (0.54) MMP2MMP9MMP8MMP13BMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138432-B1 Arylsulfonamido-substituted hydroxamic acid derivatives NOVARTIS AG (CH) 2006-11-21 US claimed
EP-1202961-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES Novartis AG (CH) 2002-05-08 EP claimed
WO-2001010827-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES NOVARTIS AG (CH) 2001-02-15 WO claimed
EP-1202961-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES NOVARTIS AG (CH) 2010-01-20 EP disclosed
EP-2085379-A1 Arylsulfonamido-substituted hydroxamic acid derivatives Novartis AG (CH) 2009-08-05 EP disclosed